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Abstract: Homoarginine, a non-proteinogenic amino acid, is formed when lysine replaces 
ornithine in reactions catalyzed by hepatic urea cycle enzymes or lysine substitutes for 
glycine as a substrate of renal arginine:glycine amidinotransferase. Decreased circulating 
homoarginine and elevated ornithine, a downstream product of arginase, predict adverse 
cardiovascular outcome. Our aim was to investigate correlates of plasma homoarginine and 
ornithine and their relations with carotid vascular structure in 40 healthy children  
and adolescents aged 3–18 years without coexistent diseases or subclinical carotid 
atherosclerosis. Homoarginine, ornithine, arginine, asymmetric dimethylarginine (ADMA) 
and symmetric dimethylarginine (SDMA) were measured by liquid chromatography-tandem 
mass spectrometry with stable isotope-labeled internal standards. Intima-media thickness 
(IMT) and extra-medial thickness (EMT) of common carotid arteries were estimated by  
B-mode ultrasound. Homoarginine correlated with arginine (r = 0.43, p = 0.005),  
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age (r = 0.42, p = 0.007) and, weakly, with an increased arginine-to-ornithine ratio, a 
putative measure of lower arginase activity (r = 0.31, p = 0.048). Ornithine correlated 
inversely with arginine (r = −0.64, p < 0.001). IMT, EMT or their sum were unrelated to 
any of the biochemical parameters (p > 0.12). Thus, opposite associations of plasma 
homoarginine and ornithine with arginine may partially result from possible involvement 
of arginase, an enzyme controlling homoarginine degradation and ornithine synthesis from 
arginine. Age-dependency of homoarginine levels can reflect developmental changes in 
homoarginine metabolism. However, neither homoarginine nor ornithine appears to be 
associated with carotid vascular structure in healthy children and adolescents.  
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1. Introduction 
Homoarginine is a non-proteinogenic, basic amino acid that differs from arginine by an additional 
methylene group in the carbon chain. Homoarginine is formed when lysine replaces ornithine in 
reactions catalyzed by hepatic enzymes of the urea cycle [1–4] or lysine substitutes for glycine as a 
substrate of renal arginine:glycine amidinotransferase (AGAT) [1,5–7]. Decreased levels of circulating 
homoarginine have recently emerged as an independent predictor of all-cause and cardiovascular 
mortality in 3305 Ludwigshafen Risk and Cardiovascular Health (LURIC) study participants referred 
for coronary angiography and in 1244 diabetic patients on maintenance hemodialysis from the 4D (Die 
Deutsche Diabetes Dialyse) study [8]. In addition, transient elevations of homoarginine, but not 
simultaneous changes in arginine or asymmetric dimethylarginine (ADMA), an endogenous nitric 
oxide (NO) synthase inhibitor, were related to enhanced endothelial function during the second and 
third trimesters of pregnancy [9,10]. The ability of homoarginine to modulate NO bioavailability in the 
presence of about 30-fold higher arginine concentrations [8] appears as intriguing as the arginine 
paradox, i.e., the capability of exogenous arginine to stimulate NO formation in spite of a much lower 
Michaelis-Menten constant (Km) of endothelial-type NO synthase (eNOS) for arginine compared to 
circulating arginine levels. Assuming an effect of homoarginine on NO bioavailability and, 
consequently, early atherogenesis, an association of homoarginine with carotid vascular structure may  
be hypothesized.  
Additionally, the LURIC study identified an independent association of cardiovascular mortality 
with higher concentrations of ornithine, a product of arginase activity [11]. However, to the best of our 
knowledge, relations of homoarginine or ornithine with carotid intima-media thickness (IMT) have not 
been reported so far. 
It has long been recognized that homoarginine levels are decreased in patients with renal 
dysfunction [8,12], in accordance with the notion of the importance of renal AGAT for homoarginine 
formation [7]. Effects of age on blood homoarginine are less clear. Although März et al. [8]  
described a weak negative correlation between homoarginine and age in the LURIC cohort (mean age,  
63 ± 11 years), Meinitzer et al. [13] have not observed any association of homoarginine and age in 
healthy adult men aged 20–75 years. 
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To the best of our knowledge, determinants of homoarginine or ornithine levels in healthy children 
have not been reported so far. Therefore, our aim was to estimate correlates of plasma homoarginine 
and ornithine and their association with carotid vascular structure in healthy subjects below 18 years of 
age. Beyond IMT, we also investigated relations between homoarginine, ornithine and carotid  
extra-medial thickness (EMT)—a recently proposed measure providing insight into adventitial 
remodeling [14,15], implicated in early atherogenesis [16–19]. As EMT had been demonstrated to be 
linked to modifiable cardiovascular risk factors more closely than IMT [14], we hypothesized that 
associations of EMT with homoarginine or ornithine might be revealed in a group of healthy children 
without coexistent diseases or subclinical carotid atherosclerosis, selected on the basis of a wide set of 
exclusion criteria.  
2. Results 
Biochemical characteristics of our study group have been presented in Table 1, as previously 
described [20]. Median plasma homoarginine concentration was 1.41 µmol/L (interquartile range, 
1.14–1.82 µmol/L), being skewed to the right, as reported previously in a cohort of 136 healthy  
adults [21]. Arginine and ornithine levels averaged 69 ± 22 (mean ± SD) µmol/L and 72 ± 32 µmol/L, 
respectively, and the mean arginine-to-ornithine ratio was 1.24 ± 0.79. Respective mean  
levels of asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA) were  
0.63 ± 0.12 µmol/L and 0.56 ± 0.10 µmol/L [20]. Median values of averaged IMT and EMT were  
0.45 mm (0.41–0.53 mm) [20] and 0.65 mm (0.56–0.78 mm), respectively.  
Table 1. Biochemical characteristics of the study subjects [20]. 
Variable  
Estimated GFR (mL/min per 1.73 m2) 122 ± 22 
LDL cholesterol (mmol/L) 2.3 ± 0.6 
HDL cholesterol (mmol/L) 1.5 (1.3–1.8) 
Triglycerides (mmol/L)  0.7 (0.5–0.9) 
Glucose (mmol/L) 4.7 ± 0.5 
Homocysteine (µmol/L) 8.9 ± 2.5 
Data are depicted as the mean ± SD or median (interquartile range). GFR: glomerular filtration rate;  
LDL: low-density lipoproteins; HDL: high-density lipoproteins. 
Natural logarithmically (ln)-transformed concentrations of homoarginine correlated positively with 
arginine (r = 0.43, p = 0.005) (Table 2) and age (r = 0.42, p = 0.007) (Figure 1). Additionally, a 
weak—albeit significant—relationship of homoarginine with an increased arginine-to-ornithine ratio 
was found (r = 0.31, p = 0.048). By multiple linear regression, ln-transformed homoarginine was 
associated with arginine (β = 0.42 ± 0.13, p = 0.003) and age (β = 0.40 ± 0.13, p = 0.005) (adjusted  
R2: 0.31, p < 0.001). 
Ornithine correlated inversely with arginine (r = −0.64, p < 0.001) and glucose (r = −0.43, p = 0.006) 
(Table 2) and tended to increase insignificantly with age (r = 0.24, p = 0.14) (Figure 2). By a multivariate 
approach, arginine (β = −0.56 ± 0.14, p < 0.001) was the only ornithine predictor (adjusted R2: 0.39, p 
< 0.001). Both homoarginine and ornithine were unrelated to ADMA or SDMA (p > 0.15).  
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Table 2. Correlation coefficients (r) between ornithine or homoarginine and biochemical 
data. ADMA, asymmetric dimethylarginine; SDMA, symmetric dimethylarginine. 
 Ln-homoarginine Ornithine 
Estimated GFR −0.11 (0.50) −0.14 (0.39) 
LDL cholesterol  −0.12 (0.45) −0.06 (0.70) 
HDL cholesterol 0.11 (0.52) 0.22 (0.18) 
Triglycerides −0.24 (0.14) −0.07 (0.65) 
Glucose 0.25 (0.12) −0.43 (0.006) 
Homocysteine 0.27 (0.10) 0.09 (0.56) 
Arginine 0.43 (0.005) −0.64 (<0.001) 
ADMA −0.05 (0.77) 0.10 (0.53) 
SDMA 0.23 (0.15) 0.09 (0.56) 
Respective p-values have been shown in parentheses. Abbreviations are as in Table 1. 
Figure 1. A positive correlation between age and natural logarithmically (ln)-transformed 
plasma levels of homoarginine.  
 
Figure 2. Lack of correlation between age and plasma ornithine levels.  
 
Neither ln (IMT) nor ln (EMT) nor ln (IMT + EMT) correlated to homoarginine, ornithine, ADMA, 
SDMA, L-arginine or the arginine-to-ornithine ratio (p > 0.12). 
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3. Discussion 
3.1. Comparison with Other Reports on Circulating Homoarginine and Ornithine 
In our healthy subjects below 18 years of age, plasma homoarginine levels were lower by almost 
50% compared to homoarginine concentrations (≈2.5 µmol/L) previously reported in 292 healthy  
non-smoking 20–75-year-old men [13] and 136 apparently healthy volunteers aged 48 ± 11 years [21]. 
In addition, serum homoarginine was intermediate (≈2.0 µmol/L) in 68 healthy juveniles aged  
8–21 years (mean, 13.2 years, i.e., higher by three years compared to our study group) [22]; 
nevertheless, correlates of homoarginine were not determined in that report. Accordingly, an increase of 
homoarginine with age in our healthy children and adolescents might result from gradual maturation of 
the pathways controlling homoarginine metabolism. An age-dependency of plasma concentrations of 
several amino acids had previously been described in a healthy pediatric population [23,24], 
nevertheless, homoarginine was not measured in those studies. Additionally, in contrast to 
homoarginine, plasma arginine was independent of age in our study group, in agreement with a 
previous report on 54 healthy children with a mean age of 11.9 ± 4.6 years [25].  
With regard to ornithine, in our subjects, the levels of this amino acid were about 50% higher 
compared to those previously described in healthy children of a similar age [23,24]. A weak increase 
in plasma ornithine between six and sixteen years of age was reported by Lepage et al. [23], which was 
confirmed in our study. 
3.2. Proposed Mechanisms of the Relations between Homoarginine, Arginine and Ornithine 
That in the present study plasma homoarginine correlated positively with arginine—in agreement 
with a report on the LURIC cohort [8]—is consistent with the notion of the predominant role of the 
promiscuous activity of renal AGAT for homoarginine formation [5–7], because AGAT transfers the 
amidino group from arginine to lysine instead of glycine. The importance of this pathway for 
homoarginine synthesis has been suggested on the basis of an increased, not decreased, homoarginine 
level in a patient with a deficiency of argininosuccinate synthase, a urea cycle enzyme involved in 
hepatic homoarginine generation [7]. Given the importance of the intestinal-renal axis in the endogenous 
formation of systemic arginine (separated from the hepatic arginine pool) [26,27], arginine synthesis 
from the gut-derived citrulline in the proximal convoluted tubule coincides in location with the site of 
the expression of AGAT [28]. As AGAT expression is upregulated by growth hormone, thyroxin [29] 
and testosterone [30], these could have contributed to the age-dependency of plasma homoarginine. 
Nevertheless, the lack of hormonal assays inevitably constrains speculations on the mechanisms 
underlying our findings. 
Keeping in mind the relevance of renal AGAT for homoarginine formation and decreased 
homoarginine concentrations in even mild renal insufficiency despite homoarginine being excreted  
in the urine [12], we expected an association of homoarginine with renal function. However, neither 
estimated glomerular filtration rate (eGFR) nor SDMA, a measure previously shown to  
inversely correlate with eGFR, also in our study group [20], was related to homoarginine levels in the 
present study.  
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In the LURIC study participants, März et al. [8] described a relationship between homoarginine and 
an increased arginine-to-ornithine ratio, a putative indirect measure of lower arginase activity [8]. In 
our hands, homoarginine was also positively related to the arginine-to-ornithine ratio, with an r-value 
similar to the LURIC cohort [8], which could be attributable [8] to the ability of homoarginine to 
inhibit arginases [31], governing the predominant pathway of arginine catabolism [27]. Nevertheless, 
compared to lysine and ornithine, homoarginine is a much weaker arginase inhibitor [31–33], and its 
plasma concentrations are about 20–80-fold lower [8]. Therefore, as homoarginine can be converted by 
arginase to lysine and urea [2,7], we can hypothesize that higher circulating homoarginine might rather 
be a consequence, not a cause, of reduced arginase activity, irrespective of the mechanism of arginase 
modulation. An altered activity of arginases might have also affected ornithine concentrations, because 
plasma levels of ornithine, a product of arginase, were inversely associated with arginine, a substrate 
of the enzyme. Accordingly, a lower activity of arginase could increase arginine availability, decrease 
ornithine synthesis and increase homoarginine levels, the latter both directly, via reduced 
homoarginine degradation, and indirectly, via enhanced homoarginine formation from lysine and 
arginine by AGAT. This hypothesis may explain the opposite associations of homoarginine and 
ornithine with arginine in our study group.  
3.3. Homoarginine and Ornithine versus the L-Arginine—NO Pathway and Carotid Vascular Structure  
Santhanam et al. [34] elegantly demonstrated that—despite a much lower Km of eNOS  
(2.9 µmol/L) [35] than arginase (1–20 mmol/L) for arginine—endothelial arginase can effectively 
compete with eNOS for the arginine substrate, due to high intracellular arginine concentrations in 
endothelial cells (about 800 µmol/L) [36–38] and a 1.5-fold higher Vmax of arginase compared to 
eNOS. As endothelial arginase is overexpressed and upregulated in aging blood vessels [39], the 
notion of arginase activity as a negative modulator of plasma homoarginine might explain a 
considerably higher ability of decreased homoarginine than decreased arginine to predict all-cause 
mortality in the LURIC study [8]. Admittedly, homoarginine by itself may replace arginine as  
a substrate for all three isoforms of NO synthase [40–42]. On the other hand, the Km value of  
neuronal-type (nNOS) and inducible-type NO synthase (iNOS) for homoarginine is higher compared 
to arginine (nNOS: 174 vs. 6 µmol/L [40], 23 vs. 2.7 µmol/L [42]; iNOS: 33 vs. 13 µmol/L [42]), and 
the relative activity of eNOS in the presence of homoarginine averages 25% with reference to  
arginine [41]. Thus, low plasma levels of homoarginine are unlikely to directly affect NO formation in 
the presence of abundant arginine (≈2.5 vs. ≈85 µmol/L [13]). Furthermore, Davids and Teerlink [43] 
recently demonstrated similar concentrations of homoarginine in peripheral blood mononuclear cells 
compared to plasma (2.4 vs. 2.0 µmol/L), whereas intracellular arginine was over seven-fold higher  
(717 vs. 98 µmol/L), which further increased the intracellular ratio of arginine to homoarginine.  
Therefore, it has been proposed that homoarginine might affect cardiovascular risk by mechanisms 
other than being a simple NO precursor [8], and the previously discussed hypothetical associations of 
homoarginine with the activity of endothelial arginases appear a plausible possibility, all the more 
because the role of arginases in endothelial dysfunction and atherogenesis, as well as increased 
vascular stiffness appears well established [34,44]. A variety of pro-atherosclerotic factors increase the 
expression/activity of arginases in endothelial cells [44], and upregulation of endothelial type II 
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arginase has been implicated in atherogenesis in apolipoprotein E-deficient mice [45]. Additionally, 
arginase inhibition prevented eNOS uncoupling, corrected endothelial dysfunction and improved aortic 
compliance in aged animals [39,46,47]. Moreover, arginase blockade protected cultured endothelial 
cells from accelerated senescence [48]. Finally, in a recent clinical study, arginase inhibition improved 
endothelial function in patients with coronary artery disease and type 2 diabetes, but not in matched 
controls [49]. Thus, hypothetical relations with high activity of arginases might possibly contribute to 
the association of low homoarginine levels with adverse cardiovascular outcome. 
On the other hand, we have observed no associations between homoarginine and either carotid IMT, 
EMT or their sum, which could be expected assuming a relevance of homoarginine for early carotid 
remodeling. In agreement with this hypothesis, low homoarginine might result from an increased 
activity of arginases that compete with eNOS for the common substrate, arginine [44]. Furthermore, 
ornithine, a downstream product of arginase, is a precursor of proline and polyamines that enhance 
collagen synthesis and vascular smooth muscle proliferation, respectively, both of which are involved 
in early arterial remodeling [34,44]. In 2236 patients from the LURIC study, Sourij et al. [11] observed 
that higher ornithine by itself, but not altered arginine or citrulline, was responsible for independent 
associations of cardiovascular mortality with a lower arginine-to-ornithine ratio or so-called  
“global arginine bioavailability ratio”, calculated as arginine divided by the sum of citrulline and 
ornithine. Moreover, in 1001 subjects participating in the Étude du Vieillissement Artériel (EVA) 
study, Dumont et al. [50] identified the relationship of a four-year increase in carotid IMT with a 
polymorphism in the gene of ornithine decarboxylase antizyme-1 that inhibits and accelerates the 
degradation of ornithine decarboxylase, a key enzyme in polyamine synthesis.  
Accordingly, as IMT and EMT include arterial media and adventitia, respectively, we expected a 
relationship between these indices (and, especially, their sum) and homoarginine or ornithine, novel 
cardiovascular outcome predictors. Nevertheless, in our hands, neither homoarginine nor ornithine  
nor the arginine-to-ornithine ratio contributed to the variability of IMT or EMT in healthy children.  
Contrary to our working hypothesis, the expected associations were not revealed in children free of the 
majority of classical risk factors previously associated with IMT or EMT in adults [14]. Therefore, 
further investigations of the relations of homoarginine and ornithine with carotid vascular structure  
are warranted.  
3.4. Study Limitations 
First, the small number of the subjects is the major limitation of the study. Nevertheless, we made 
every effort to recruit exclusively healthy children and adolescents by means of a wide range of 
exclusion criteria, including preclinical carotid atherosclerosis [20]. Second, we have not measured 
serum alkaline phosphatase levels, although changes in protein turnover in children have been 
proposed as the basis of age-dependent decline in ADMA, correlating also positively to alkaline 
phosphatase [22], considered a biomarker of bone growth rate. Moreover, the ability of homoarginine 
to inhibit alkaline phosphatases might have contributed to associations of homoarginine with bone 
density and metabolism in elderly women [51]. Third, we have not estimated neither arginase activity 
nor any index of NO formation, which constrains mechanistic considerations based on our findings 
with regard to homoarginine metabolism and NO bioavailability.  
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4. Experimental Section  
4.1. Subjects 
We studied the previously described group of 40 children and adolescents (33 boys and 7 girls; 
mean age, 10.1 ± 3.6 years; range, 3.4–17.9 years) [20]. As reported before, exclusion criteria included 
congenital heart or pulmonary defects, clinical or biochemical evidence of renal or hepatic pathology, 
hypertension, diabetes, obesity and any other significant chronic coexistent diseases, acute disorders or 
relevant abnormalities in routine blood or urine analyses, considerably elevated C-reactive protein, as 
well as ultrasound evidence of atherosclerotic plaques in carotid arteries [20]. In accordance with the 
Helsinki Declaration, the protocol had been approved by the ethics committee of the Medical 
University of Silesia (No. KNW-6501-28/08), and written informed consent was obtained from the 
parents of each participant. 
4.2. Biochemical Assays  
Venous blood samples were drawn after an overnight fast and centrifuged, and portions of serum 
and plasma (collected from ethylenediaminetetraacetic acid-anticoagulated blood) were separated and 
frozen initially at −20 °C and, then, at −70 °C, until assayed [20]. In addition to lipids and  
glucose—measured by standard methods—C-reactive protein, homocysteine and creatinine were 
assessed by immunoturbidimetry (Roche Diagnostics, Basel, Switzerland), a chemiluminescent 
microparticle immunoassay (Abbott Diagnostics, Abbott Park City, IL, USA) and the Jaffe method 
with the isotope dilution mass spectrometry (IDMS)-traceable calibration (Roche Hitachi Chemistry 
Analyzer, Roche Diagnostics), respectively [20]. As previously described [20], an eGFR was 
calculated from serum creatinine and height by the revised bedside Schwartz equation [52], a formula 
which has been validated also for children and adolescents with normal renal function [53]. 
The quantification of homoarginine in plasma was performed by high performance liquid 
chromatography-tandem mass spectrometry (LC-MS/MS). The overall procedure of sample 
preparation and chromatography/detection followed the previously described method for the 
quantification of arginine, ADMA and SDMA [54]. Owing to the very selective and sensitive MS 
detection, no interferences from endogenous substances were observed. Stable isotope-labeled  
13C6-arginine was used as an internal standard for endogenous homoarginine. The calibration function 
was linear in the range of 0.2–10 µmol/L (R2 = 1.000). The precision and accuracy of the quality 
control samples were better than 3% at all concentrations studied. Details of the LC-MS/MS 
measurements of arginine, ADMA and SDMA in the same plasma samples were described previously 
with 13C6-arginine and 
2H6-ADMA as internal standards for arginine and both ADMA and SDMA, 
respectively [20,55]. Ornithine was assayed by LC-MS/MS with 2H6-ornithine as an internal standard 
and intra-day and inter-day relative standard deviations of 1.1% and 3.5%, respectively [56].  
4.3. Carotid Ultrasound 
As described previously [20], the common carotid artery, carotid bulb and internal carotid artery 
were visualized on both sides in the longitudinal plane using a high-resolution ultrasound device  
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(iU22 xMATRIX Ultrasound System, Philips Healthcare, Best, The Netherlands) equipped with a  
12-MHz linear digital ultrasound by an investigator (J. Rycaj), who was blinded to biochemical data. 
Beyond exclusion of atherosclerotic plaques, images were captured and stored for off-line analysis of 
carotid IMT and EMT. IMT was estimated within a 1 cm segment immediately proximal to the carotid 
bifurcation on the far wall (distal to the skin) of the common carotid artery and corresponded  
to the distance between the lumen-intima interface and media-adventitia interface [20,57]. Following 
Skilton et al. [14], EMT was measured along a distinct 0.3–1.0 cm long arterial segment 1–1.5 cm 
proximal to the carotid bulb, where the distance between the carotid artery and jugular vein is smallest. 
For EMT measurements, images were focused on the arterial near wall (proximal to the skin) and the 
venous far wall. EMT was defined as the distance between the arterial media-adventitia interface and 
venous lumen-intima margin, thus consisting of arterial adventitia, interstitial tissue and the entire 
venous wall [14,15]. The final values of IMT and EMT were averaged from 3 end-diastolic 
measurements per each side. We also computed a combined measure as a sum of IMT and EMT, 
because this parameter had previously exhibited stronger correlations with some risk factors compared 
to IMT or EMT [14]. 
4.4. Statistical Analysis  
Continuous data are presented as means ± SD or medians and interquartile range for not normally 
distributed values. The accordance with a normal distribution was confirmed by Lilliefors’ test, and  
ln-transformation was applied when necessary for skewed variables (homoarginine, high-density 
lipoproteins (HDL) cholesterol, triglycerides, IMT, EMT). Relations between variables were 
represented by Pearson’s correlation coefficients (r). Independent determinants of plasma 
homoarginine or ornithine were assessed by multiple linear regression, including only covariates for 
which the p-value at a univariate analysis did not exceed 0.10.  
Our study design allowed us to detect bivariate correlations within the study group as a whole at an  
r-value of 0.42 with a statistical power of 80% at a type I error rate of 0.05.  
A p-value below 0.05 was inferred to be significant. Statistical tests were performed using 
STATISTICA (data analysis software system, version 10.0.1011.0; StatSoft, Inc., Tulsa, OK, USA). 
5. Conclusions  
Opposite associations of plasma homoarginine and ornithine with arginine may partially result from 
possible involvement of arginase, an enzyme controlling both homoarginine degradation and ornithine 
formation from arginine. The age-dependency of homoarginine levels can reflect developmental 
changes in pathways governing homoarginine metabolism. However, neither homoarginine nor 
ornithine appears to be associated with carotid IMT or EMT in healthy children and adolescents. 
Whether homoarginine or ornithine can be related to carotid vascular structure in other clinical settings 
remains to be elucidated. 
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